A significant proportion of patients who stop GLP-1 receptor agonist therapy eventually reinitiate treatment, according to recent analysis of real-world treatment patterns. While 92% initially discontinue due to gastrointestinal side effects and 68% cite cost concerns, approximately 64% of these patients resume medication within defined follow-up periods.
This finding challenges the notion that stopping GLP-1 therapy represents permanent abandonment of diabetes management. Instead, discontinuation often reflects temporary barriers—whether side effect-related, financial, or preference-driven—that may be overcome through clinical intervention or natural resolution.
Cost and affordability barriers affect nearly two-thirds of discontinuers, highlighting the critical role of medication access programs and insurance coverage in sustaining treatment. Read the full article on GMJ Newsroom.
Was this article helpful?
